Oct 1st 2013, 17:48, by Sean Williams, The Motley Fool
Lexicon Pharmaceuticals reports its findings on a proof-of-concept type 2 diabetes study and shareholders certainly like what they see. Can Lexicon head even higher?
You are receiving this email because you subscribed to this feed at blogtrottr.com.
No comments:
Post a Comment